Sunshine Biopharma says study shows MR1-114 SARS-CoV-2 inhibitor effective in mice, potent in vitro across variants
SBFM•Study results on MR1-114
Sunshine Biopharma reported publication of Journal of Medicinal Chemistry data on PLpro inhibitor MR1-114 targeting SARS-CoV-2.
- The study showed nanomolar in vitro potency across variants.
- Oral dosing reduced viral replication in a SARS-CoV-2 mouse model.
- Mouse efficacy was described as comparable to nirmatrelvir in Paxlovid, supporting potential clinical development for SARS coronavirus infections.
